Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ANET
3. NKE
4. BE
5. PANW
6. CL
7. SNDK
8. TAP
9. DELL
10. ROIV

Go back to Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
(NASDAQ: IOVA) Delayed: 8.79 --0 (-0%)
Previous Close $8.79    52 Week High $ 
Open $8.79    52 Week Low $ 
Day High $8.79    P/E N/A 
Day Low $8.79    EPS $ 
Volume 4,230